The Center for Biosimilars (CB) interviewed Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, and editorial board member of The Center for Biosimilars, on where the field stands today.
CB: What would be an ideal way to expand familiarity with biosimilars within the medical healthcare community?
Fuhr: Educational programs are the best way and this includes such entities as the FDA, pharmaceutical companies, and payers to educate physicians and patients.
CB: How can the oncology community in particular benefit from extended knowledge of biosimilars and, conversely, benefit the biosimilar industry?
Fuhr: Oncology drugs are some of the highest priced drugs. Biosimilars can decrease the price of these drugs, thus increasing access and improving the quality of life of more patients.
CB: Do you believe that biosimilar treatment options will make treatment more affordable?
Fuhr: Yes. Competition will lead to lower prices and we have seen this in the European Union.
CB: What would be the best-case scenario for biosimilar incorporation into mainstream medicine from a healthcare policy/cost perspective?
Fuhr: As patents expire and more biosimilars enter [the market], prices will decrease. It will take a while for the market to fully develop.
CB: What, in your opinion, is the greatest benefit represented by biosimilar uptake?
Fuhr: Lower prices and greater access, which will benefit consumers and help decrease prices in the healthcare market. Also, it will result in innovators’ attempting to find benefits on new drugs as profits on old drugs decline. Biosimilars will thus benefit society.
CB: Do you recognize the need for educating healthcare professionals and patients on biosimilars?
Fuhr: Many patients and physicians are unaware of what biosimilars are and the process that they must go through to achieve FDA approval. People are not going to purchase or prescribe something which they do not understand.
CB: Would biosimilars raise challenges with formulary management for health plans and for clinical pharmacies?
Fuhr: Any time a new alternative comes to market, formulary management and clinical pharmacies must make a decision on the circumstances under which they will adopt the alternative. So, they must decide on the quality and price of the product to determine not only if it will go onto the formulary but also on what tier in terms of health plans.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.